A method for detecting and diagnosing early stage (I/II) ovarian cancer in a subject comprising: (a) obtaining a serum sample from the subject and obtaining a normal serum control sample; (b) isolating from the sample obtained in (a) total RNA comprising mRNA encoding at least 2 serine proteases selected from the group consisting of kallikrein 6, kallikrein 7, and PRSS8; (c) transforming the isolated total RNA of (b) into cDNA comprising serine protease cDNA; (d) amplifying the cDNA of (c); (e) measuring a level of amplified serine protease cDNA comprising at least 2 serine proteases selected from the group consisting of kallikrein 6, kallikrein 7, and PRSS8 in (d) as a measure of expression of amplified serine protease mRNA; (f) comparing the level of expression of the amplified serine protease mRNA in (e) expressed by the subject with the level of expression of the amplified serine protease mRNA in (e) expressed by the normal serum control sample, wherein an increased level of expression of the serine protease mRNA expressed by the subject compared to the level of expression of the serine protease mRNA expressed by the normal serum control sample is indicative of possible early stage ovarian cancer in the subject; (g) when (f) is indicative of early stage (I/II) ovarian cancer in the subject, isolating total RNA comprising serine protease mRNA from an ovarian tissue sample previously obtained from said subject; (h) transforming the isolated total RNA of (g) into cDNA comprising serine protease cDNA; (i) amplifying the cDNA of (h); (j) measuring a level of amplified serine protease cDNA in (i) as a measure of expression of amplified serine protease mRNA; (k) comparing the level of expression of the amplified serine protease mRNA in (j) expressed by the subject with the level of expression of the amplified serine protease mRNA in (j) expressed by a normal ovarian tissue control sample, wherein an increased level of expression of serine protease mRNA expressed by the subject compared to the level of expression of the serine protease mRNA expressed by the normal ovarian tissue control sample is indicative of possible early stage ovarian cancer in the subject; (l) when both (f) and (k) are indicative of early stage ovarian cancer, diagnosing early stage (I/II) ovarian cancer in the subject; and (m) designating the subject diagnosed in step as suitable for receiving a treatment regimen effective to treat the early stage (I/II) ovarian cancer in said subject. (a) obtaining a serum sample from the subject and obtaining a normal serum control sample; (b) isolating from the sample obtained in (a) total RNA comprising mRNA encoding at least 2 serine proteases selected from the group consisting of kallikrein 6, kallikrein 7, and PRSS8; (c) transforming the isolated total RNA of (b) into cDNA comprising serine protease cDNA; (d) amplifying the cDNA of (c); (e) measuring a level of amplified serine protease cDNA comprising at least 2 serine proteases selected from the group consisting of kallikrein 6, kallikrein 7, and PRSS8 in (d) as a measure of expression of amplified serine protease mRNA; (f) comparing the level of expression of the amplified serine protease mRNA in (e) expressed by the subject with the level of expression of the amplified serine protease mRNA in (e) expressed by the normal serum control sample, wherein an increased level of expression of the serine protease mRNA expressed by the subject compared to the level of expression of the serine protease mRNA expressed by the normal serum control sample is indicative of possible early stage ovarian cancer in the subject; (g) when (f) is indicative of early stage (I/II) ovarian cancer in the subject, isolating total RNA comprising serine protease mRNA from an ovarian tissue sample previously obtained from said subject; (h) transforming the isolated total RNA of (g) into cDNA comprising serine protease cDNA; (i) amplifying the cDNA of (h); (j) measuring a level of amplified serine protease cDNA in (i) as a measure of expression of amplified serine protease mRNA; (k) comparing the level of expression of the amplified serine protease mRNA in (j) expressed by the subject with the level of expression of the amplified serine protease mRNA in (j) expressed by a normal ovarian tissue control sample, wherein an increased level of expression of serine protease mRNA expressed by the subject compared to the level of expression of the serine protease mRNA expressed by the normal ovarian tissue control sample is indicative of possible early stage ovarian cancer in the subject; (l) when both (f) and (k) are indicative of early stage ovarian cancer, diagnosing early stage (I/II) ovarian cancer in the subject; and (m) designating the subject diagnosed in step as suitable for receiving a treatment regimen effective to treat the early stage (I/II) ovarian cancer in said subject.